What is the role of infliximab in the treatment of granulomatosis with polyangiitis (GPA)?

Updated: Oct 09, 2019
  • Author: Christopher L Tracy, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print
Answer

Infliximab is a chimeric monoclonal antibody to tumor necrosis factor–α (TNF-α) that consists of murine antigen recognition sites bound to human Fc regions. The results in various studies and/or case reports have been mixed, so it is not currently possible to comment on the efficacy of infliximab. [96, 97] The safety of infliximab therapy in patients with GPA, similar to the results in trials with etanercept, seems to be the limiting factor, as there were increased serious infections in the infliximab group. [98] Further studies are needed.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!